000			02322 a2200757 4500
005			20250518083544.0
264		0	_c20201027
008			202010s 0 0 eng d
022			_a1476-5551
024	7		_a10.1038/s41375-020-0725-0 _2doi
040			_aNLM _beng _cNLM
100	1		_aOssenkoppele, G J
245	0	0	_aLenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. _h[electronic resource]
260			_bLeukemia _c07 2020
300			_a1751-1759 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCytarabine _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aInduction Chemotherapy _xmortality
650	0	4	_aLenalidomide _xadministration & dosage
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMale
650	0	4	_aMyelodysplastic Syndromes _xdrug therapy
650	0	4	_aPrognosis
650	0	4	_aRemission Induction
650	0	4	_aSurvival Rate
700	1		_aBreems, D A
700	1		_aStuessi, G
700	1		_avan Norden, Y
700	1		_aBargetzi, M
700	1		_aBiemond, B J
700	1		_aA von dem Borne, P
700	1		_aChalandon, Y
700	1		_aCloos, J
700	1		_aDeeren, D
700	1		_aFehr, M
700	1		_aGjertsen, B
700	1		_aGraux, C
700	1		_aHuls, G
700	1		_aJanssen, J J J W
700	1		_aJaspers, A
700	1		_aJongen-Lavrencic, M
700	1		_ade Jongh, E
700	1		_aKlein, S K
700	1		_avan der Klift, M
700	1		_avan Marwijk Kooy, M
700	1		_aMaertens, J
700	1		_aMichaux, L
700	1		_avan der Poel, M W M
700	1		_avan Rhenen, A
700	1		_aTick, L
700	1		_aValk, P
700	1		_aVekemans, M C
700	1		_avan der Velden, W J F M
700	1		_ade Weerdt, O
700	1		_aPabst, T
700	1		_aManz, M
700	1		_aLöwenberg, B
773	0		_tLeukemia _gvol. 34 _gno. 7 _gp. 1751-1759
856	4	0	_uhttps://doi.org/10.1038/s41375-020-0725-0 _zAvailable from publisher's website
999			_c30597175 _d30597175